-
Sciwind Biosciences’ Ecnoglutide Accepted for Review by China’s NMPA for Type 2 Diabetes
•
China-based Sciwind Biosciences Co., Ltd has announced that the National Medical Products Administration (NMPA) has accepted its market filing for the Category 1 product ecnoglutide. The targeted indication for this treatment is blood glucose control in adult patients with type 2 diabetes. Ecnoglutide’s Therapeutic Potential and Clinical Trial SuccessEcnoglutide is…
-
China’s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea
•
China’s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South Korea’s HK inno.N Corporation (KOSDAQ: 195940) for the development and commercialization of ecnoglutide injection (XW003), a novel glucagon-like peptide-1 (GLP-1) analog, for the treatment of type 2 diabetes, obesity, and metabolic associated severe hyperglycemia (MASH)…
